Therapeutic plasmapheresis in idiopathic membranous nephropathy anti‐PLA2R‐related: A case series

Abstract Membranous nephropathy is the most common cause of nephrotic syndrome (NS) in non‐diabetic adults; in 80% of patients it is idiopathic (PMN). PMN has an autoimmune pathogenesis, 70%‐85% of patients have increased titer of antibodies to the podocyte membrane antigen PLA2R. The etiological, prognostic and predictive role of the Ab anti‐PLA2R is demonstrated. Standard therapy consists in anti‐CD20 monoclonal antibody rituximab (RTX) combined with steroids or immunosuppressants according to the risk of progressive loss of kidney function. The immunosuppressive therapies are potentially associated to severe adverse events that lead to protocol suspension. Given their pivotal pathogenetic role, serum clearance of anti‐PLA2R with plasmapheresis could have a beneficial impact on NS, particularly in patients not requiring or tolerating standard therapies. In this series, we present three cases of PMN anti‐PLA2R related treated with a RTX plus plasmapheresis approach and demonstrate its overall effective role on anti‐PLA2R titer and clinical outcomes.